{"id":52829,"date":"2026-11-17T14:13:24","date_gmt":"2026-11-17T14:13:24","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/"},"modified":"2026-11-17T14:13:24","modified_gmt":"2026-11-17T14:13:24","slug":"ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/","title":{"rendered":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p><strong>ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells<\/strong><\/p>\n<p><strong>IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027<\/strong><\/p>\n<p>NEW YORK, Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing Multispecific\u2122 therapeutics in oncology, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301.<\/p>\n<p>ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.<\/p>\n<p>&#8220;Submission of the IND for ISB 2301 marks an important milestone in advancing IGI\u2019s multispecific oncology pipeline into clinical development,\u201d\u00a0<strong>said Lida Pacaud, M.D., President and Chief Executive Officer, IGI<\/strong>. \u201cThis pentaspecific candidate is designed to integrate multiple tumor-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in patients with solid tumors in 2027.\u201d<\/p>\n<p>ISB 2301 was engineered using IGI\u2019s proprietary BEAT<sup>\u00ae<\/sup> Multispecific Platform and is designed to recognize three tumor-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.<\/p>\n<p>In preclinical studies, ISB 2301 demonstrated favorable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned evaluation of its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced solid tumors.<\/p>\n<p><strong>About IGI<\/strong><\/p>\n<p>IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics\u2122 powered by its proprietary BEAT<sup>\u00ae<\/sup> technology platform. The platform has demonstrated clinical proof of concept through ISB 2001, an investigational CD38 \u00d7 BCMA \u00d7 CD3 trispecific T-cell engager that has shown promising anti-tumor activity and favorable safety profile in patients with heavily pretreated relapsed\/refractory multiple myeloma in an investigational Phase 1 study. IGI is committed to delivering breakthrough curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SdHc7bPzfsy_afUnimCbNNM4f_RRstSFjqaxziUhiW3EY88oB4RJ7McmcJFkoLakqdW8LV7_fvyttqKy2PCvkp5vmu0bx_AfynLfLRGA8F4=\" rel=\"nofollow\" target=\"_blank\" title=\"www.IGInnovate.com\">www.IGInnovate.com<\/a>.<\/p>\n<p><strong>IGI Corporate Communications:<\/strong><\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7RD1o4fTRFMq--Zq5sFKtIyj-_trllVtyUkzfy9HFlI2FJgUUvLblneLaQFtidvt7se3Xw4HEpgYtma9EF0skTVeqnI6l9N44hPdfqgGGyKYx4CjEa7f7qBmeTlZpOuIjjwa6rj2tdoyUOXOwMlJgDPwFIABj_S6aOaf0kzfuoI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>Corporate.communications@IGInnovate.com<\/u><\/a><\/p>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":52830,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/1efc56d9-10ca-47f6-b389-0f549311aa9e","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-52829","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.5.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Gias Ul Hassan\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.5.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"All Online Bangla Newspapers - Daily online newspapers Bangla, Bangla News online, All Bangla Newspaper, All online Bangla news\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\" \/>\n\t\t<meta property=\"og:description\" content=\"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"299\" \/>\n\t\t<meta property=\"og:image:height\" content=\"86\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-11-17T14:13:24+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-11-17T14:13:24+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\" \/>\n\t\t<meta name=\"twitter:description\" content=\"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#blogposting\",\"name\":\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\",\"headline\":\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\",\"author\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/Resource\\\/Download\\\/1efc56d9-10ca-47f6-b389-0f549311aa9e\"},\"datePublished\":\"2026-11-17T14:13:24+00:00\",\"dateModified\":\"2026-11-17T14:13:24+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#webpage\"},\"articleSection\":\"GlobeNewsWire\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewsWire\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"position\":2,\"name\":\"GlobeNewsWire\",\"item\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/category\\\/globenewswire\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#listItem\",\"name\":\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#listItem\",\"position\":3,\"name\":\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewsWire\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#organization\",\"name\":\"All Online Bangla Newspapers\",\"description\":\"Daily online newspapers Bangla, Bangla News online, All Bangla Newspaper, All online Bangla news\",\"url\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Daily-Bangla-News.png\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#organizationLogo\",\"width\":299,\"height\":86,\"caption\":\"Daily Bangla News\"},\"image\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/author\\\/giasulhassan\\\/#author\",\"url\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/author\\\/giasulhassan\\\/\",\"name\":\"Gias Ul Hassan\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#webpage\",\"url\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/\",\"name\":\"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\",\"description\":\"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/Resource\\\/Download\\\/1efc56d9-10ca-47f6-b389-0f549311aa9e\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#mainImage\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\\\/#mainImage\"},\"datePublished\":\"2026-11-17T14:13:24+00:00\",\"dateModified\":\"2026-11-17T14:13:24+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#website\",\"url\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/\",\"name\":\"All Online Bangla Newspapers\",\"description\":\"Daily online newspapers Bangla, Bangla News online, All Bangla Newspaper, All online Bangla news\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/allonlinebanglanewspapers.com\\\/news\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","description":"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on","canonical_url":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#blogposting","name":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","headline":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","author":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/author\/giasulhassan\/#author"},"publisher":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/1efc56d9-10ca-47f6-b389-0f549311aa9e"},"datePublished":"2026-11-17T14:13:24+00:00","dateModified":"2026-11-17T14:13:24+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#webpage"},"isPartOf":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#webpage"},"articleSection":"GlobeNewsWire"},{"@type":"BreadcrumbList","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#listItem","position":1,"name":"Home","item":"https:\/\/allonlinebanglanewspapers.com\/news\/","nextItem":{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewsWire"}},{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/category\/globenewswire\/#listItem","position":2,"name":"GlobeNewsWire","item":"https:\/\/allonlinebanglanewspapers.com\/news\/category\/globenewswire\/","nextItem":{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#listItem","name":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors"},"previousItem":{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#listItem","position":3,"name":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","previousItem":{"@type":"ListItem","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewsWire"}}]},{"@type":"Organization","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#organization","name":"All Online Bangla Newspapers","description":"Daily online newspapers Bangla, Bangla News online, All Bangla Newspaper, All online Bangla news","url":"https:\/\/allonlinebanglanewspapers.com\/news\/","logo":{"@type":"ImageObject","url":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#organizationLogo","width":299,"height":86,"caption":"Daily Bangla News"},"image":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/author\/giasulhassan\/#author","url":"https:\/\/allonlinebanglanewspapers.com\/news\/author\/giasulhassan\/","name":"Gias Ul Hassan"},{"@type":"WebPage","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#webpage","url":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/","name":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","description":"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#website"},"breadcrumb":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#breadcrumblist"},"author":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/author\/giasulhassan\/#author"},"creator":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/author\/giasulhassan\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/1efc56d9-10ca-47f6-b389-0f549311aa9e","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#mainImage"},"primaryImageOfPage":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/#mainImage"},"datePublished":"2026-11-17T14:13:24+00:00","dateModified":"2026-11-17T14:13:24+00:00"},{"@type":"WebSite","@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#website","url":"https:\/\/allonlinebanglanewspapers.com\/news\/","name":"All Online Bangla Newspapers","description":"Daily online newspapers Bangla, Bangla News online, All Bangla Newspaper, All online Bangla news","inLanguage":"en-US","publisher":{"@id":"https:\/\/allonlinebanglanewspapers.com\/news\/#organization"}}]},"og:locale":"en_US","og:site_name":"All Online Bangla Newspapers - Daily online newspapers Bangla, Bangla News online, All Bangla Newspaper, All online Bangla news","og:type":"article","og:title":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","og:description":"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on","og:url":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/","og:image":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png","og:image:secure_url":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png","og:image:width":299,"og:image:height":86,"article:published_time":"2026-11-17T14:13:24+00:00","article:modified_time":"2026-11-17T14:13:24+00:00","twitter:card":"summary_large_image","twitter:title":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","twitter:description":"ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027 NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on","twitter:image":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-content\/uploads\/2023\/11\/Daily-Bangla-News.png"},"aioseo_meta_data":{"post_id":"52829","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2026-11-17 14:14:27","updated":"2026-11-17 14:14:27","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/allonlinebanglanewspapers.com\/news\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/allonlinebanglanewspapers.com\/news\/category\/globenewswire\/\" title=\"GlobeNewsWire\">GlobeNewsWire<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tIchnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/allonlinebanglanewspapers.com\/news\/"},{"label":"GlobeNewsWire","link":"https:\/\/allonlinebanglanewspapers.com\/news\/category\/globenewswire\/"},{"label":"Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors","link":"https:\/\/allonlinebanglanewspapers.com\/news\/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors\/"}],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/52829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=52829"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/52829\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/52830"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=52829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=52829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=52829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}